CN110199015A - 修饰干细胞记忆t细胞、其制造方法与使用方法 - Google Patents
修饰干细胞记忆t细胞、其制造方法与使用方法 Download PDFInfo
- Publication number
- CN110199015A CN110199015A CN201780073874.1A CN201780073874A CN110199015A CN 110199015 A CN110199015 A CN 110199015A CN 201780073874 A CN201780073874 A CN 201780073874A CN 110199015 A CN110199015 A CN 110199015A
- Authority
- CN
- China
- Prior art keywords
- cell
- manufacturing
- modified stem
- stem cell
- memory
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000003071 memory t lymphocyte Anatomy 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 238000004519 manufacturing process Methods 0.000 title 1
- 210000000130 stem cell Anatomy 0.000 title 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 238000002659 cell therapy Methods 0.000 abstract 1
- 238000012986 modification Methods 0.000 abstract 1
- 230000004048 modification Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1241—Nucleotidyltransferases (2.7.7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/515—CD3, T-cell receptor complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/53—CD2
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/99—Coculture with; Conditioned medium produced by genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/90—Vectors containing a transposable element
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Virology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Nanotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medical Informatics (AREA)
- Diabetes (AREA)
Abstract
本公开提供了一种生产修饰的干细胞样记忆T细胞(例如CAR‑T细胞)的方法,用于施用于受试者作为例如过继细胞疗法。
Applications Claiming Priority (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662402707P | 2016-09-30 | 2016-09-30 | |
US62/402707 | 2016-09-30 | ||
US201762502508P | 2017-05-05 | 2017-05-05 | |
US62/502508 | 2017-05-05 | ||
US201762553058P | 2017-08-31 | 2017-08-31 | |
US62/553058 | 2017-08-31 | ||
US201762556309P | 2017-09-08 | 2017-09-08 | |
US62/556309 | 2017-09-08 | ||
PCT/US2017/054799 WO2018064681A1 (en) | 2016-09-30 | 2017-10-02 | Modified stem cell memory t cells, methods of making and methods of using same |
Publications (1)
Publication Number | Publication Date |
---|---|
CN110199015A true CN110199015A (zh) | 2019-09-03 |
Family
ID=60245180
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201780073874.1A Pending CN110199015A (zh) | 2016-09-30 | 2017-10-02 | 修饰干细胞记忆t细胞、其制造方法与使用方法 |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP3519561A1 (zh) |
JP (4) | JP2019528760A (zh) |
KR (3) | KR102588469B1 (zh) |
CN (1) | CN110199015A (zh) |
AU (3) | AU2017337147A1 (zh) |
CA (3) | CA3036926C (zh) |
IL (3) | IL287286B (zh) |
SG (2) | SG11201901959YA (zh) |
WO (1) | WO2018064681A1 (zh) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20190119636A1 (en) | 2017-10-23 | 2019-04-25 | Poseida Therapeutics, Inc. | Modified stem cell memory t cells, methods of making and methods of using same |
CA3036926C (en) * | 2016-09-30 | 2022-05-31 | Poseida Therapeutics, Inc. | Modified stem cell memory t cells, methods of making and methods of using same |
US11278570B2 (en) | 2016-12-16 | 2022-03-22 | B-Mogen Biotechnologies, Inc. | Enhanced hAT family transposon-mediated gene transfer and associated compositions, systems, and methods |
EP3555273B1 (en) | 2016-12-16 | 2024-05-22 | B-Mogen Biotechnologies, Inc. | ENHANCED hAT FAMILY TRANSPOSON-MEDIATED GENE TRANSFER AND ASSOCIATED COMPOSITIONS, SYSTEMS, AND METHODS |
EP3351263A1 (en) | 2017-01-20 | 2018-07-25 | Universitätsklinikum Hamburg-Eppendorf | Pharmaceutical preparation for treating or preventing tissue adhesion |
BR112020003403A2 (pt) | 2017-08-18 | 2020-08-25 | Neutrolis Inc. | enzimas de dnase engenheiradas e uso na terapia |
CA3104288A1 (en) | 2018-06-21 | 2019-12-26 | B-Mogen Biotechnologies, Inc. | Enhanced hat family transposon-mediated gene transfer and associated compositions, systems, and methods |
US11058724B2 (en) * | 2018-10-08 | 2021-07-13 | Neutrolis, Inc. | Methods of using DNASE1-like 3 in therapy |
CN112996911A (zh) | 2018-10-08 | 2021-06-18 | 纽特雷斯股份有限公司 | 用于制造和疗法的脱氧核糖核酸酶的工程改造 |
US10988746B2 (en) | 2018-10-08 | 2021-04-27 | Neutrolis, Inc. | Manufacturing and engineering of DNASE enzymes for therapy |
US11352613B2 (en) | 2019-02-04 | 2022-06-07 | Neutrolis, Inc. | Engineered human extracellular DNASE enzymes |
US11529427B2 (en) | 2019-02-15 | 2022-12-20 | Crispr Therapeutics Ag | Gene editing for hemophilia A with improved factor VIII expression |
KR20220004028A (ko) * | 2019-04-26 | 2022-01-11 | 알로젠 테라퓨틱스 인코포레이티드 | 동종 car t 세포를 제조하는 방법 |
CN110358734B (zh) | 2019-06-13 | 2020-08-25 | 首都医科大学宣武医院 | 以Tcm为主要效应成分的CAR-T制备方法及其应用 |
EP4110356A4 (en) * | 2020-02-28 | 2024-03-27 | Wisconsin Alumni Research Foundation | NON-VIRAL GENERATION OF CHIMERIC ANTIGEN RECEPTOR T CELLS OBTAINED BY GENE EDITING |
CA3171092A1 (en) * | 2020-03-13 | 2021-09-16 | Stephen John GOULD | Selectable marker proteins, expression vectors, for the production of virus-like particles for therapeutic and prophylactic applications |
EP4298205A1 (en) * | 2021-02-23 | 2024-01-03 | Poseida Therapeutics, Inc. | Genetically modified induced pluripotent stem cells and methods of use thereof |
CN114990061B (zh) * | 2022-06-30 | 2023-08-29 | 河南省人民医院 | 一种诱导扩增中央记忆性t细胞的培养方法 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100287633A1 (en) * | 2009-02-26 | 2010-11-11 | Transposagen Bio | Hyperactive PiggyBac Transposases |
WO2015142675A2 (en) * | 2014-03-15 | 2015-09-24 | Novartis Ag | Treatment of cancer using chimeric antigen receptor |
US20150291975A1 (en) * | 2014-04-09 | 2015-10-15 | Dna2.0, Inc. | Enhanced nucleic acid constructs for eukaryotic gene expression |
WO2016033690A1 (en) * | 2014-09-04 | 2016-03-10 | Stemcell Technologies Inc. | Soluble antibody complexes for t cell or nk cell activation and expansion |
CN105408473A (zh) * | 2013-05-14 | 2016-03-16 | 得克萨斯州大学系统董事会 | 工程化嵌合抗原受体(car)t细胞的人应用 |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
US5266491A (en) | 1989-03-14 | 1993-11-30 | Mochida Pharmaceutical Co., Ltd. | DNA fragment and expression plasmid containing the DNA fragment |
US5580734A (en) | 1990-07-13 | 1996-12-03 | Transkaryotic Therapies, Inc. | Method of producing a physical map contigous DNA sequences |
US5641670A (en) | 1991-11-05 | 1997-06-24 | Transkaryotic Therapies, Inc. | Protein production and protein delivery |
US5733761A (en) | 1991-11-05 | 1998-03-31 | Transkaryotic Therapies, Inc. | Protein production and protein delivery |
WO1995030413A1 (fr) * | 1994-05-10 | 1995-11-16 | The Kitasato Institute | Accelerateur de proliferation de cellules souches hematopoietiques |
US6218185B1 (en) | 1996-04-19 | 2001-04-17 | The United States Of America As Represented By The Secretary Of Agriculture | Piggybac transposon-based genetic transformation system for insects |
US6835394B1 (en) | 1999-12-14 | 2004-12-28 | The Trustees Of The University Of Pennsylvania | Polymersomes and related encapsulating membranes |
US6962810B2 (en) | 2000-10-31 | 2005-11-08 | University Of Notre Dame Du Lac | Methods and compositions for transposition using minimal segments of the eukaryotic transformation vector piggyBac |
US7105343B1 (en) | 2000-10-31 | 2006-09-12 | University Of Notre Dame Du Lac | Methods and compositions for transposition using minimal segments of the eukaryotic transformation vector Piggybac |
IL152904A0 (en) * | 2002-01-24 | 2003-06-24 | Gamida Cell Ltd | Utilization of retinoid and vitamin d receptor antagonists for expansion of renewable stem cell populations |
BR0314402A (pt) * | 2002-08-19 | 2005-07-19 | Gamida Cell Ltd | Expansão ex-vivo de populações de células raìzes em culturas celulares mononucleares |
US8808748B2 (en) | 2010-04-20 | 2014-08-19 | Vindico NanoBio Technology Inc. | Biodegradable nanoparticles as novel hemoglobin-based oxygen carriers and methods of using the same |
PT2661275T (pt) | 2011-01-07 | 2019-04-24 | Poseida Therapeutics Inc | Composições e métodos para a entrega a tumores de agentes ligantes de elevada afinidade para o oxigénio |
WO2016022805A1 (en) | 2014-08-08 | 2016-02-11 | Vindico NanoBio Technology Inc. | Compositions and methods for inducing nanoparticle-mediated microvascular embolization of tumors |
AU2013221672B2 (en) * | 2012-02-13 | 2017-11-09 | Seattle Children's Hospital D/B/A Seattle Children's Research Institute | Bispecific chimeric antigen receptors and therapeutic uses thereof |
WO2014153470A2 (en) * | 2013-03-21 | 2014-09-25 | Sangamo Biosciences, Inc. | Targeted disruption of t cell receptor genes using engineered zinc finger protein nucleases |
KR20170032406A (ko) * | 2014-07-15 | 2017-03-22 | 주노 쎄러퓨티크스 인코퍼레이티드 | 입양 세포 치료를 위한 조작된 세포 |
EP3018200A1 (en) * | 2014-11-07 | 2016-05-11 | Fondazione Matilde Tettamanti e Menotti de Machi Onlus | Improved method for the generation of genetically modified cells |
AU2015358413A1 (en) | 2014-12-05 | 2017-06-29 | Poseida Therapeutics, Inc. | Compositions and methods for inducing nanoparticle-mediated microvascular embolization of tumors |
CA3197849A1 (en) * | 2014-12-29 | 2016-07-07 | Novartis Ag | Methods of making chimeric antigen receptor-expressing cells |
US10456452B2 (en) | 2015-07-02 | 2019-10-29 | Poseida Therapeutics, Inc. | Compositions and methods for improved encapsulation of functional proteins in polymeric vesicles |
US20170000743A1 (en) | 2015-07-02 | 2017-01-05 | Vindico NanoBio Technology Inc. | Compositions and Methods for Delivery of Gene Editing Tools Using Polymeric Vesicles |
CA3036926C (en) * | 2016-09-30 | 2022-05-31 | Poseida Therapeutics, Inc. | Modified stem cell memory t cells, methods of making and methods of using same |
-
2017
- 2017-10-02 CA CA3036926A patent/CA3036926C/en active Active
- 2017-10-02 IL IL287286A patent/IL287286B/en unknown
- 2017-10-02 WO PCT/US2017/054799 patent/WO2018064681A1/en unknown
- 2017-10-02 JP JP2019517047A patent/JP2019528760A/ja active Pending
- 2017-10-02 CA CA3105873A patent/CA3105873A1/en not_active Abandoned
- 2017-10-02 KR KR1020207026327A patent/KR102588469B1/ko active IP Right Grant
- 2017-10-02 SG SG11201901959YA patent/SG11201901959YA/en unknown
- 2017-10-02 AU AU2017337147A patent/AU2017337147A1/en not_active Abandoned
- 2017-10-02 KR KR1020197011671A patent/KR20190063468A/ko not_active IP Right Cessation
- 2017-10-02 EP EP17794119.2A patent/EP3519561A1/en active Pending
- 2017-10-02 KR KR1020237007633A patent/KR20230035467A/ko not_active Application Discontinuation
- 2017-10-02 SG SG10202007963SA patent/SG10202007963SA/en unknown
- 2017-10-02 CN CN201780073874.1A patent/CN110199015A/zh active Pending
- 2017-10-02 CA CA3154236A patent/CA3154236C/en active Active
-
2019
- 2019-03-04 IL IL265157A patent/IL265157B/en active IP Right Grant
-
2020
- 2020-08-25 IL IL276907A patent/IL276907B/en unknown
- 2020-09-01 AU AU2020227020A patent/AU2020227020B2/en active Active
- 2020-10-05 JP JP2020168576A patent/JP2021006057A/ja active Pending
-
2021
- 2021-09-27 JP JP2021156988A patent/JP2021191312A/ja active Pending
-
2022
- 2022-09-23 AU AU2022235633A patent/AU2022235633A1/en active Pending
-
2024
- 2024-05-09 JP JP2024076779A patent/JP2024096417A/ja active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100287633A1 (en) * | 2009-02-26 | 2010-11-11 | Transposagen Bio | Hyperactive PiggyBac Transposases |
CN105408473A (zh) * | 2013-05-14 | 2016-03-16 | 得克萨斯州大学系统董事会 | 工程化嵌合抗原受体(car)t细胞的人应用 |
WO2015142675A2 (en) * | 2014-03-15 | 2015-09-24 | Novartis Ag | Treatment of cancer using chimeric antigen receptor |
US20150291975A1 (en) * | 2014-04-09 | 2015-10-15 | Dna2.0, Inc. | Enhanced nucleic acid constructs for eukaryotic gene expression |
WO2016033690A1 (en) * | 2014-09-04 | 2016-03-10 | Stemcell Technologies Inc. | Soluble antibody complexes for t cell or nk cell activation and expansion |
Non-Patent Citations (1)
Title |
---|
JACOB PLIETH & EDWIN ELMHIRST: "Shifting CAR-Ts Into a Higher Gear", 《EVALUATE》 * |
Also Published As
Publication number | Publication date |
---|---|
JP2024096417A (ja) | 2024-07-12 |
JP2019528760A (ja) | 2019-10-17 |
CA3105873A1 (en) | 2018-04-05 |
AU2020227020A1 (en) | 2020-09-17 |
IL276907A (en) | 2020-10-29 |
CA3154236A1 (en) | 2018-04-05 |
CA3036926C (en) | 2022-05-31 |
WO2018064681A1 (en) | 2018-04-05 |
IL265157A (en) | 2019-05-30 |
JP2021006057A (ja) | 2021-01-21 |
CA3036926A1 (en) | 2018-04-05 |
JP2021191312A (ja) | 2021-12-16 |
KR20230035467A (ko) | 2023-03-13 |
IL265157B (en) | 2021-01-31 |
AU2020227020B2 (en) | 2022-10-13 |
SG11201901959YA (en) | 2019-04-29 |
KR20190063468A (ko) | 2019-06-07 |
KR20200108927A (ko) | 2020-09-21 |
IL287286A (en) | 2021-12-01 |
KR102588469B1 (ko) | 2023-10-11 |
IL287286B (en) | 2022-09-01 |
EP3519561A1 (en) | 2019-08-07 |
SG10202007963SA (en) | 2020-10-29 |
AU2022235633A1 (en) | 2022-10-20 |
AU2017337147A1 (en) | 2019-03-21 |
IL276907B (en) | 2021-12-01 |
CA3154236C (en) | 2023-08-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110199015A (zh) | 修饰干细胞记忆t细胞、其制造方法与使用方法 | |
JOP20170041B1 (ar) | اجسام مضادة ضد vista (b7h5) | |
MX2024006992A (es) | Anticuerpos contra ligando 1 de muerte programada. | |
PE20210107A1 (es) | Anticuerpos anti-cd3 y metodos de uso | |
MX2023011785A (es) | Metodos y composiciones para produccion de proteina de clara de huevo. | |
PH12020551436A1 (en) | Intracellular delivery of biomolecules to modify immune response | |
SG10201914126RA (en) | Anti-ox40 antibodies and their uses | |
MX2019008419A (es) | Métodos de fabricación de harinas de nueces y formulaciones para inmunoterapia oral. | |
EP4374863A3 (en) | Methods for generating stem cell-derived beta cells and uses thereof | |
MX2022000893A (es) | Metodo de obtencion de mitocondrias de celulas y mitocondrias obtenidas. | |
AU2016250905A8 (en) | Generation of muscle-lineage cells from stem cells | |
EP3708605A4 (en) | HYDROGEL PARTICLE AND ITS PRODUCTION PROCESS, CELL OR CELLULAR STRUCTURE EACH CONTAINING A HYDROGEL PARTICLE, PROCESS FOR EVALUATING THE ACTIVITY OF A CELL USING A HYDROGEL PARTICLE, AND USE OF A PARTICLE OF HYDROGEL AS A LONG-RELEASE PREPARATION | |
MX2019011999A (es) | Metodo y usos de exudados encapsulados y biomasa seca de euglena para la union de metal. | |
EP3719117A4 (en) | EECTODERMAL MESENCHYMAL STEM CELLS AND METHOD FOR PRODUCING THEM | |
MX366112B (es) | Medio de cultivo celular y metodos de produccion de anticuerpos. | |
WO2019126641A3 (en) | Modulation of frataxin expression | |
MX2021005157A (es) | Composiciones, metodos para hacer y utilizar extracto de salvado de arroz. | |
EP3671451A4 (en) | PROCESS FOR AUTOMATICALLY RELEASING A RESOURCE OCCUPIED BY A BACKGROUND PROCESS OF A TERMINAL, INFORMATION MEDIA AND TERMINAL | |
CL2020001137A1 (es) | Anticuerpos anti-apoc3 y métodos de uso de estos. | |
BR112017001696A2 (pt) | composições de célula-tronco e métodos de produção de células-tronco para aplicações terapêuticas | |
EP3705567A4 (en) | CELL CHIP AND THREE-DIMENSIONAL TISSUE CHIP AND PROCESS FOR THEIR PRODUCTION | |
MX2017014653A (es) | Estructura de capas adhesiva revestida con gel de silicona. | |
EP3719113A4 (en) | CELL CULTURE CONTAINER WITH LONG-TERM CULTURE AND METHOD OF MANUFACTURING THEREOF | |
EP3315601A4 (en) | METHOD FOR CULTURING ANIMAL CELL COMPOSITION, METHOD FOR PRODUCING ANIMAL CELL COMPOSITION THEREFOR AND ANIMAL CELL COMPOSITION | |
EP3728301A4 (en) | ANTIBODIES TO CENTRIN-1, METHOD OF PRODUCING AND USING THEREOF |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |